RedHill Biopharma (RDHL) Research & Development (2012 - 2023)

RedHill Biopharma (RDHL) has 12 years of Research & Development data on file, last reported at $1.2 million in Q2 2023.

• On a quarterly basis, Research & Development fell 15.29% year-over-year to $1.2 million in Q2 2023; TTM through Jun 2023 was $5.1 million, a 68.71% decrease from a year earlier, with the FY2025 full-year figure at $2.0 million, up 27.39% from the prior year.
• Research & Development for Q2 2023 stood at $1.2 million, up from $1.1 million in the prior quarter.
• Over the last five years, Research & Development for RDHL reached as high as $10.3 million in Q2 2021 and fell as low as $1.1 million in Q1 2023.
• Historically, Research & Development has averaged $4.1 million across 5 years, with a median of $3.1 million in 2020.
• Across the five-year window, Research & Development jumped 221.34% in 2021 and sank 85.75% in 2022, its largest moves.
• Year by year, Research & Development stood at $2.3 million in 2019, then soared by 171.92% to $6.2 million in 2020, then slipped by 5.19% to $5.9 million in 2021, then sank by 80.69% to $1.1 million in 2022, then rose by 10.06% to $1.2 million in 2023.
• Per Business Quant data, the three most recent Research & Development figures were $1.2 million in Q2 2023, $1.1 million in Q1 2023, and $1.1 million in Q4 2022.